Neoadjuvant immunotherapy for non-small cell lung cancer:State of the art

查看全文 作　　者：Jin [1]Kang;Chao [1]Zhang;Wen-Zhao [1,2]Zhong

机构地区：[1]Guangdong Lung Cancer Institute,Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,School of Medicine,Guangzhou,Guangdong 510080,P.R.China;[2]Southern Medical University,Guangzhou,Guangdong 510515,P.R.China

出　　处：《Cancer Communications》索引2021年第41卷第4期,共16页

基　　金：supported by the High-Level Hospital Construction Project(grant No.Dfjh201801);the National Natural Science Foundation of China(grant No.81872510 and 81802266);the Guangdong Provincial People’s Hospital Young Talent Project(grant No.Gdpphytp201902);the Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine(grant No.2017b030314120);the Guangdong Basic and Applied Basic Research Foundation(grant No.2019b1515130002). 摘　　要：Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy.Immune checkpoint inhibitors(ICIs)have rapidly evolved from investigational drugs to standard of care for the treatment ofmetastatic non-small cell lung cancer(NSCLC).In particular,antibodies that block inhibitory immune checkpoints,such as programmed cell death protein 1(PD-1)and programmed cell death 1 ligand 1(PD-L1),have revolutionized the treatment of advanced NSCLC,when administered alone or in combination with chemotherapy.Immunotherapy is associated with higher response rates,improved overall survival(OS),and increased tolerability compared with conventional cytotoxic chemotherapy.These benefits may increase the utility of immunotherapy and its combinational use with chemotherapy in the neoadjuvant treatment of patients with NSCLC.Early findings from various ongoing clinical trials suggest that neoadjuvant ICIs alone or combined with chemotherapy may significantly reduce systemic recurrence and improve long-term OS or cure rates in resectable NSCLC.Here we further summarize the safety and efficacy of various neoadjuvant treatment regimens including immunotherapy from ongoing clinical trials and elaborate the role of neoadjuvant immunotherapy in patients with resectable NSCLC.In addition,we discuss several unresolved challenges,including the evaluations to assess neoadjuvant immunotherapy response,the role of adjuvant treatment after neoadjuvant immunotherapy,the efficacy of treatment for oncogenic-addicted tumors,and predictive biomarkers.We also provide our perspective on ways to overcome current obstacles and establish neoadjuvant immunotherapy as a standard of care. 关键词：CHEMOIMMUNOTHERAPY clinical trials imaging IMMUNOTHERAPY NEOADJUVANT non-small cell lung cancer PERIOPERATIVE RADIOTHERAPY surgery

相关文献

参考文献（108）
引证文献（36）
耦合文献（180）

参考文献(108)

引证文献(36)

耦合文献(180)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Neoadjuvant immunotherapy for non-small cell lung cancer:State of the art

参考文献(108)

引证文献(36)

耦合文献(180)

用户提示